Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Urgency For Approval Of OTC Naloxone In US Weighed Against Using Untested Package Labeling

Feb 16 2023

• By Malcolm Spicer

• Source: Shutterstock

Related Content

OTC Naloxone In US Could Limit Access Due To Costs, Comments On Emergent Switch NDA Argue

Feb 13 2023

Naloxone OTC Switch NDA Has US FDA Concerned Labeling Will Cause User Error, Delay Delivery

Feb 14 2023

Emergent Expects Moving OTC Naloxone Directions On Package To Sway US FDA Advisory Panel

Feb 14 2023

On Emergent OTC Naloxone Switch, Tight Timeline For FDA Decision Following Advisory Committee

Jan 06 2023

Emergent’s OTC Naloxone Single-Panel Instruction List Prompts Doubletake From US FDA Officials

Feb 16 2023

Related Companies

Emergent BioSolutions, Inc.

Additional Topics

International United States Advisory Committees FDA Prescription To OTC Switch Business Strategies Commercial Companies Compliance Consumer Drug Approval Standards Ingredients Manufacturing OTC Drugs Policy Regulation Retail Research & Development Safety

More from Regulation

More from Policy & Regulation

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window